DURECT Corporation Reports Fourth Quarter 2000 and Year End Financial Results

Download PDF:

CUPERTINO, Calif., Feb. 15 /PRNewswire/ —
DURECT Corporation (Nasdaq: DRRX) announced today financial results for the
three months and year ended December 31, 2000.

The Company’s net loss attributable to common stockholders for the three
months ended December 31, 2000 was $4.9 million or 11 cents per share,
compared to a net loss of $3.6 million, or 60 cents per share, for the three
months ended December 31, 1999. On a pro forma basis, DURECT’s net loss for
the three months ended December 31, 1999 was $3.3 million, or 11 cents per
share. For the year ended December 31, 2000, DURECT’s net loss was
$20.8 million, or $1.22 per share, compared to a net loss of $9.3 million, or
$1.76 per share, for the year ended December 31, 1999. On a pro forma basis,
the net loss for the year ended December 31, 2000 was $19.9 million, or
54 cents per share, compared to a net loss of $8.7 million, or 37 cents per
share, for the year ended December 31, 1999. Concurrent with the company’s
initial public offering on September 28, 2000, all shares of preferred stock
were converted into common stock. Pro forma calculations assume the conversion
of all preferred stock, at the date of issuance, into common stock. DURECT’s
results include non-cash charges for the amortization of intangible assets and
stock-based compensation of $1.4 million and $5.9 million for the fourth
quarter and the year ended December 31, 2000, respectively and $0.6 million
and $0.9 million for the same periods in 1999.

“We are pleased with the company’s progress over the past year. For the
year 2000, we met our key company milestones, including commencement of Phase
II clinical trials for our lead product, beginning construction on our
commercial manufacturing facility, and completing a prototype design for our
spinal delivery program for our second product, DUROS hydromorphone for
end-stage cancer pain. We completed two financings, including an initial
public offering of DURECT common stock, which together raised net proceeds of
approximately $109 million,” said James E. Brown, President and Chief
Executive Officer of DURECT. “We are also very pleased at the progress that we
have made in 2001 with our patient enrollment for our Phase II trial for DUROS
sufentanil. The accelerated pace exceeds our expectations, and we expect this
trial to complete 8-10 weeks ahead of the previously anticipated schedule.”

The increase in net loss for 2000 compared to the net loss in 1999 was
primarily due to the company’s preparation for and commencement of Phase II
clinical trials for its lead product, DUROS sufentanil, for the treatment of
chronic pain. The increases in operating expenses were primarily due to
increases in research and development expenses, selling, general and
administrative expenses and non-cash items including amortization and
stock-based compensation. The increase in research and development expenses
was attributable to activity related to DUROS sufentanil Phase II trials,
increases in research and development personnel and related payroll, and
increases in contract research and development. The increase in selling,
general and administrative expenses was primarily due to an increase in
general and administrative personnel and related expenses necessary to support
DURECT’s growth.

At December 31, 2000, the Company had cash, cash equivalents, and
investments of $106.1 million, compared to $18.9 million as of
December 31, 1999. This increase was primarily due to the proceeds from the
sale of common stock from DURECT’s initial public offering, which closed on
October 3rd, 2000.

The Company also announced that its 2001 Annual Meeting of Stockholders
has been scheduled for June 27, 2001.

DURECT Corporation is pioneering the development and commercialization of
pharmaceutical systems to deliver the right drug to the right site in the
right amount at the right time. DURECT’s pharmaceutical systems combine
technology innovations from the medical device and drug delivery industries
with proprietary pharmaceutical and biotechnology drug formulations. These
capabilities can enable new drug therapies or optimize existing therapies
based on a broad range of compounds, including small molecule pharmaceuticals
as well as biotechnology molecules such as proteins, peptides and genes.
DURECT’s initial portfolio of products combine the DUROS technology, a proven
and patented drug delivery platform licensed for specified fields of use from
ALZA Corporation, with drugs for which medical data on efficacy and safety are

DURECT’s lead product in development, DUROS sufentanil, is for the
treatment of chronic pain. DUROS sufentanil is designed to deliver sufentanil
on a continuous basis for 3 months for the treatment of chronic pain. Annual
sales of opioids for the treatment of chronic pain are in excess of
$1 billion. DURECT’s second product, DUROS hydromorphone, is a DUROS-based
pharmaceutical system for the delivery of hydromorphone to the spine for the
treatment of end-stage cancer pain. DURECT is also selling FDA cleared
catheters for the delivery of fluids to the inner ear. DURECT also
manufactures, sells and distributes the ALZET(R) osmotic pump product for use
in laboratory research.

Founded in 1998, the Company is headquartered in Cupertino, CA. The
Company’s World Wide Web site can be accessed at http://www.www.durect.com. To
join DURECT’s email alert service, please register by selecting “Email Alerts”
on the main Investor Relations web page at http://www.www.durect.com.

DUROS is a registered trademark of ALZA Corporation.

The statements in this press release regarding DURECT’s products in
development, product development plans, clinical trials, and expected product
benefits are forward-looking statements involving risks and uncertainties that
could cause actual results to differ materially from those in such forward-
looking statements. Potential risks and uncertainties include, but are not
limited to, DURECT’s ability to develop, manufacture and commercialize its
products, complete successful clinical trials, obtain product approvals from
regulatory agencies, build a manufacturing facility, marketplace acceptance of
DURECT’s products and DURECT’s ability to manage its growth and costs. Further
information regarding these and other risks is included in the company’s S-1
registration statement, filed with the SEC on September 22, 2000 and its
424(b) prospectus filed with the SEC on September 28, 2000 and its Quarterly
Report on Form 10Q for the quarter ended September 30, 2000 filed with the SEC
on November 13, 2000.

There will be a conference call at 4:30 p.m. EST today to discuss DURECT’s
fourth quarter and year-end financial results as well as the outlook for 2001.
This call will be broadcast live over the Internet at http://www.www.durect.com
under “Investor Relations.” If you are unable to participate during the live
webcast, the call will be archived at:
Minimum Requirements to listen to broadcast: The RealPlayer software,
downloadable free from http://www.real.com/products/player/index.html, and at
least a 14.4Kbps connection to the Internet. If you experience problems
listening to the broadcast, send an email to webmaster@vdat.com.)

For further information please contact:

DURECT Corporation

Schond L. Greenway

Director, Investor Relations

Phone: (408) 777-1417


                              DURECT CORPORATION
                   (in thousands, except per share amounts)

                                       Quarter ended          Year ended
                                        December 31,          December 31,
                                     2000        1999      2000        1999*
                                        (unaudited)    (unaudited)

    Revenue, net                       $973         $86    $3,155        $86
    Cost of goods sold (1)              685          39     1,941         39
    Gross profit                        288          47     1,214         47

    Operating expenses:
         Research and development     4,028       2,069    12,669      5,181
         Research and development
          to related party               40         321       666      1,182
         Selling, general and
          administrative              1,504         644     4,874      2,109
         Amortization of intangible
          assets                        342          69       850         69
         Stock-based compensation
          (1)                         1,046         514     4,978        865
    Total operating expenses          6,960       3,617    24,037      9,406

    Loss from operations             (6,672)     (3,570)  (22,823)    (9,359)

    Other income (expense):
         Interest income              1,781         303     3,103        678
         Interest expense               (43)         (7)     (131)       (27)
    Net other income                  1,738         296     2,972        651
    Net Loss                         (4,934)     (3,274)  (19,851)    (8,708)

    Accretion of cumulative
     dividends on Series B
     convertible preferred stock         --         331       972        602

    Net loss attributable
     to common stockholders         $(4,934)    $(3,605) $(20,823)   $(9,310)

    Net loss per common share,
     basic and diluted               $(0.11)     $(0.60)   $(1.22)    $(1.76)

    Shares used in computing basic
     and diluted net loss per share  44,126       6,000    17,120      5,291

    Pro forma net loss per share,
     basic and diluted                           $(0.11)   $(0.54)    $(0.37)

    Shares used in computing pro
     forma net loss per share                    29,928    36,659     23,771

    (1) Stock-based compensation
     related to the following:

    Cost of goods sold                  $22        $ --       $65       $ --
    Research and development            741         316     3,426        485
    Selling, general and
     administrative                     305         198     1,552        380
                                     $1,068        $514    $5,043       $865

*derived from audited financial statements.

                              DURECT CORPORATION
                           CONDENSED BALANCE SHEETS
                                (in thousands)

                                                December 31,      December 31,
                                                    2000              1999*
    Current assets:
        Cash, cash equivalents and short-
         term investments                          $104,432           $16,598
        Inventories and other current assets          4,881               869
    Total current assets                            109,313            17,467

    Property and equipment, net                       4,472             1,271
    Intangible assets, net                            5,175             1,390
    Long-term investments                             1,652             2,335

    Total assets                                   $120,612           $22,463

    Liabilities and stockholders' equity
    Current liabilities:
        Accounts payable and accrued liabilities     $3,846            $1,413
    Equipment financing obligations,
     current portion                                    407               133
    Total current liabilities                         4,253             1,546

    Equipment financing obligations,
     noncurrent portion                               1,105               189

    Stockholders' equity                            115,254            20,728

    Total liabilities and stockholders' equity     $120,612           $22,463

*derived from audited financial statements.

CONTACT: Schond L. Greenway, Director, Investor Relations of DURECT
orporation, 408-777-1417, or Schond.Greenway@durect.com/

Scroll to Top